For the quarter ending 2026-03-31, RANI had -$8,974K decrease in cash & cash equivalents over the period. -$6,512K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -8,015 | -9,074 | -7,914 | -23,962 |
| Loss on disposal of property and equipment | - | 0 | 0 | - |
| Stock-based compensation expense | 2,084 | 2,238 | 2,343 | 7,217 |
| Impairment loss | - | 0 | - | - |
| Depreciation and amortization | 161 | 186 | 223 | 491 |
| Non-cash operating lease expense | 477 | 481 | 472 | 955 |
| Warrant issued for services provided | - | - | 0 | 152 |
| Warrant modification expense | - | - | 15 | - |
| Amortization of debt discount and issuance costs | 0 | 33 | 58 | 116 |
| Loss on extinguishment of debt | - | -576 | - | - |
| Warrant issued for services provided | - | -152 | - | - |
| Modification expense related to warrants | - | 15 | - | - |
| Net accretion and amortization of investments in marketable securities | 244 | 120 | 0 | 158 |
| Accounts receivable | 0 | 2,470 | 0 | -428 |
| Contract asset | 0 | -428 | - | - |
| Prepaid expenses and other current assets | 87 | 1,058 | -46 | -820 |
| Accounts payable | 549 | -2,158 | 669 | 439 |
| Accrued expenses and other current liabilities | 763 | 3,176 | -550 | 558 |
| Other long term assets | - | - | - | 47 |
| Deferred revenue | -1,708 | 8,539 | 0 | - |
| Operating lease liabilities | -477 | -483 | -472 | -954 |
| Net cash used in operating activities | -6,497 | 294 | -5,063 | -13,945 |
| Proceeds from maturities of marketable securities | 21,000 | 0 | 0 | 26,750 |
| Purchases of marketable securities | 23,435 | 30,972 | 0 | 2,720 |
| Purchases of property and equipment | 15 | 0 | 0 | 88 |
| Net cash (used in)/provided by investing activities | -2,450 | -30,972 | 0 | 23,942 |
| Proceeds from exercise of warrants issued-July Two Thousand Twenty Four And October Two Thousand Twenty Four Securities Purchase Agreement | - | 3,869 | - | - |
| Proceeds from issuance of common stock-October Securities Purchase Agreement | - | 0 | - | - |
| Proceeds from issuance of common stock-July Two Thousand Twenty Five Securities Purchase Agreement | - | 0 | 2,811 | - |
| Proceeds from issuance of common stock-July Two Thousand Twenty Four Securities Purchase Agreement | - | - | 0 | - |
| Proceeds from issuance of common stock-July Securities Purchase Agreement | - | 0 | - | - |
| Issuance of common stock under employee stock purchase plan | - | 15 | 0 | 46 |
| Proceeds from employee stock purchase plan | 0 | 2 | 5 | 5 |
| Proceeds from issuance of common stock-Private Placement Securities Purchase Agreement | - | 49,788 | - | - |
| Proceeds from exercise of series d warrants | - | 4,530 | - | - |
| Proceeds from exercise of stock options | - | 10 | 0 | 0 |
| Tax withholdings paid on behalf of employees for net share settlement | 32 | 21 | 7 | 31 |
| Repayment of debt | 0 | 9,472 | 3,750 | 7,500 |
| Exercise of pre-funded warrants in connection with the private placement, net of issuance costs of (5) | -3,864 | - | -68 | 3,937 |
| Net cash used in financing activities | -27 | 44,852 | -1,009 | -3,543 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash equivalents | -8,974 | 14,174 | -6,072 | 6,454 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 18,818 | 4,644 | 4,262 | - |
| Cash, cash equivalents and restricted cash equivalents, end of period | 9,844 | 18,818 | 4,644 | - |
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)